S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:LVTX

LAVA Therapeutics (LVTX) Stock Price, News & Analysis

$3.33
-0.58 (-14.83%)
(As of 03/28/2024 ET)
Today's Range
$3.31
$3.93
50-Day Range
$1.53
$4.03
52-Week Range
$1.13
$6.47
Volume
490,993 shs
Average Volume
3.08 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

LAVA Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
80.2% Upside
$6.00 Price Target
Short Interest
Healthy
2.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.24mentions of LAVA Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.41) to ($1.77) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.91 out of 5 stars

Medical Sector

654th out of 939 stocks

Pharmaceutical Preparations Industry

310th out of 441 stocks

LVTX stock logo

About LAVA Therapeutics Stock (NASDAQ:LVTX)

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

LVTX Stock Price History

LVTX Stock News Headlines

$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
LAVA Therapeutics NV (LVTX)
PCSA, ONCO and KAVL among mid-day movers
LAVA Therapeutics N.V. (LVTX)
LAVA Therapeutics NV LVTX
JMP Securities Remains a Buy on LAVA Therapeutics (LVTX)
See More Headlines
Receive LVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LAVA Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/16/2023
Today
3/28/2024
Next Earnings (Estimated)
6/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LVTX
Fax
N/A
Employees
69
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+80.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-41,970,000.00
Net Margins
-620.09%
Pretax Margin
-615.97%

Debt

Sales & Book Value

Annual Sales
$6.77 million
Book Value
$3.39 per share

Miscellaneous

Free Float
N/A
Market Cap
$84.42 million
Optionable
Optionable
Beta
0.64
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Stephen Allen Hurly M.B.A. (Age 56)
    M.Sc., CEO, President & Executive Director
  • Mr. Fred M. Powell CPA (Age 63)
    Chief Financial Officer
  • Dr. Hans van der Vliet M.D. (Age 50)
    Ph.D., Chief Scientific Officer
  • Ms. Amy Garabedian J.D. (Age 48)
    General Counsel & Corporate Secretary
  • Mr. Wouter van Hunnik
    VP & Head of Human Resources
  • Dr. Ton Adang Ph.D. (Age 63)
    Chief Development Officer
  • Dr. Charles Q. Morris M.D. (Age 59)
    MBChB, MRCP (UK), Ph.D., Chief Medical Officer

LVTX Stock Analysis - Frequently Asked Questions

Should I buy or sell LAVA Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LAVA Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LVTX shares.
View LVTX analyst ratings
or view top-rated stocks.

What is LAVA Therapeutics' stock price target for 2024?

2 brokers have issued 12 month target prices for LAVA Therapeutics' stock. Their LVTX share price targets range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 80.2% from the stock's current price.
View analysts price targets for LVTX
or view top-rated stocks among Wall Street analysts.

How have LVTX shares performed in 2024?

LAVA Therapeutics' stock was trading at $1.58 at the beginning of the year. Since then, LVTX stock has increased by 110.8% and is now trading at $3.33.
View the best growth stocks for 2024 here
.

Are investors shorting LAVA Therapeutics?

LAVA Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 322,100 shares, an increase of 476.2% from the February 29th total of 55,900 shares. Based on an average daily trading volume, of 1,710,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 2.3% of the company's stock are sold short.
View LAVA Therapeutics' Short Interest
.

When is LAVA Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 13th 2024.
View our LVTX earnings forecast
.

How were LAVA Therapeutics' earnings last quarter?

LAVA Therapeutics (NASDAQ:LVTX) posted its quarterly earnings data on Thursday, November, 16th. The company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.15. The firm had revenue of $0.05 million for the quarter. LAVA Therapeutics had a negative net margin of 620.09% and a negative trailing twelve-month return on equity of 68.54%.

When did LAVA Therapeutics IPO?

LAVA Therapeutics (LVTX) raised $100 million in an IPO on Thursday, March 25th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and SVB Leerink acted as the underwriters for the IPO and Kempen & Co. was co-manager.

Who are LAVA Therapeutics' major shareholders?

LAVA Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Novo Holdings A S (7.41%), Citadel Advisors LLC (0.09%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of LAVA Therapeutics?

Shares of LVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LVTX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners